Have a feature idea you'd love to see implemented?
Let us know!
PLX Protalix BioTherapeutics Inc
Price (delayed)
$1.03
Market cap
$75.75M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.22
Enterprise value
$78.5M
Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®. Protalix was the first company to
Highlights
The gross profit has dropped by 75% year-on-year and by 67% since the previous quarter
Protalix BioTherapeutics's quick ratio has shrunk by 58% YoY
Key stats
What are the main financial stats of PLX
Market
Valuations
Earnings
Shares outstanding
73.54M
Market cap
$75.75M
Enterprise value
$78.5M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.64
Price to sales (P/S)
1.98
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.06
Revenue
$38.05M
EBIT
-$14.45M
EBITDA
-$13.19M
Free cash flow
-$4.18M
Per share
Balance sheet
Liquidity
EPS
-$0.22
Free cash flow per share
-$0.06
Book value per share
$0.39
Revenue per share
$0.52
TBVPS
$1.25
Total assets
$91.54M
Total liabilities
$62.96M
Debt
$26.15M
Equity
$28.58M
Working capital
$19.4M
Debt to equity
0.92
Current ratio
1.33
Quick ratio
0.95
Net debt/EBITDA
-0.21
Margins
Efficiency
Dividend
EBITDA margin
-34.7%
Gross margin
32.2%
Net margin
-38.6%
Operating margin
-38.9%
Return on assets
-16.6%
Return on equity
-45.1%
Return on invested capital
-35.7%
Return on capital employed
-43%
Return on sales
-38%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
PLX stock price
How has the Protalix BioTherapeutics stock price performed over time
Intraday
0.98%
1 week
-5.5%
1 month
-4.63%
1 year
-32.24%
YTD
-42.13%
QTD
0.98%
Financial performance
How have Protalix BioTherapeutics's revenue and profit performed over time
Revenue
$38.05M
Gross profit
$12.25M
Operating income
-$14.79M
Net income
-$14.69M
Gross margin
32.2%
Net margin
-38.6%
The gross profit has dropped by 75% year-on-year and by 67% since the previous quarter
Protalix BioTherapeutics's gross margin has shrunk by 55% YoY and by 48% QoQ
Protalix BioTherapeutics's revenue has decreased by 44% YoY and by 36% from the previous quarter
Growth
What is Protalix BioTherapeutics's growth rate over time
Valuation
What is Protalix BioTherapeutics stock price valuation
P/E
N/A
P/B
2.64
P/S
1.98
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.06
Protalix BioTherapeutics's equity has decreased by 27% YoY and by 4% QoQ
PLX's P/B is 20% below its last 4 quarters average of 3.3
Protalix BioTherapeutics's revenue has decreased by 44% YoY and by 36% from the previous quarter
PLX's price to sales (P/S) is 16% higher than its 5-year quarterly average of 1.7 and 4.2% higher than its last 4 quarters average of 1.9
Efficiency
How efficient is Protalix BioTherapeutics business performance
Protalix BioTherapeutics's return on equity has shrunk by 123% YoY
Dividends
What is PLX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for PLX.
Financial health
How did Protalix BioTherapeutics financials performed over time
PLX's total assets is 45% greater than its total liabilities
Protalix BioTherapeutics's quick ratio has shrunk by 58% YoY
The company's current ratio has shrunk by 58% YoY and by 3.6% QoQ
PLX's debt is 8% less than its equity
The debt to equity is up by 37% year-on-year and by 3.4% since the previous quarter
Protalix BioTherapeutics's equity has decreased by 27% YoY and by 4% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.